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Abstract
Cells of the immune system spontaneously recognize autologous tumor cells and T cells are
believed to be the main effector cells for the immune surveillance of cancer. Recent advances in
our understanding of basic and tumor immunology together with methodological developments
implies that tumor specific T cells can now be studied functionally, phenotypically as well as
molecularly. T cells recognize peptide antigens in the context of MHC molecules through the
clonally distributed T-cell receptor (TCR), thus, the clonal distribution of the TCR offers the means
to detect and track specific T cells based upon detection of the unique TCR. In this review, we
present and discuss available data on TCR utilization of tumor specific T cells in murine models as
well as spontaneous and treatment induced anti-tumor T-cell responses in humans.
Background
During the past decade our knowledge of the interplay
between cancer cells and cells of the immune system has
increased tremendously. In particular, advances in our
understanding of T-cell recognition and priming, together
with the processing and presentation of peptide antigens
in the context of MHC molecules, has opened new ave-
nues for characterization of antigens expressed by tumor
cells – recognized by T cells. Since the first human tumor
antigen recognized by T cells was described in melanoma
more than a decade ago [1], an overwhelming number of
human tumor antigens recognized by T cells has been
characterized [2]. Over the past years, melanoma has con-
sistently been the focus for extensive research in the field
of tumor immunology – as clearly reflected by the data
provided in present review. However, it has become clear
that cancers in general elicit cellular immune responses
[3]. Clearly, this has increased the potential clinical appli-
cability of well characterized peptide antigens in the treat-
ment of metastatic cancers, and thereby called further
attention to the characterization of tumor associated pep-
tide antigen. More importantly, however, new methods
and technologies have provided scientists and clinicians
with the means to dig deeper and faster. In this respect, the
capacity to predict the peptides capable of binding to an
HLA molecule [4], the introduction of methods to culture
dendritic cells in vitro [5], highly sensitive methods for
detection of specific T cells, e.g. ELISPOT [6], as well as the
introduction of recombinant HLA molecules as tetrameric
[7] or multimeric complexes [8], has played important
roles. Following the characterization of peptide antigens
recognized by autologous T cells on the surface of cancer
cells, numerous small therapeutic vaccination trials
against cancer have been performed aiming at the induc-
tion of clinically relevant anti-tumor CTL responses.
Although some reports have demonstrated impressive
clinical responses [9,10], in most cases vaccination has
not yet convincingly demonstrated any impact on the
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course of the disease [11]. In spite of the fact that clinical
endpoints remain the most important success criteria for
any given therapy, strategies that utilize biological modi-
fiers in the treatment of disease may eventually benefit sig-
nificantly from the increased insight that follows
biological monitoring [12]. To this end, novel insight into
the cells and molecules that govern the success or failure
of any given therapy may lead the way to significant
improvements of current therapeutic strategies. Conse-
quently, characterization and tracking of the T-cell recep-
tor (TCR) utilized by tumor specific T cells may reveal
important information as to the biology of anti-tumor T-
cell responses. In the present article we will review current
knowledge on TCR repertoire usage and clonality of anti-
tumor T-cell responses. The nomenclatur of Arden et al. is
adopted throughout [13].
TCR repertoire analyses
Interest and early attempts to analyze tumor infiltrating
lymphocytes (TIL) were initiated in part based on the fact
that a crude infiltrate of T cells in melanoma lesions rep-
resents a positive prognostic factor [14]. While initial
studies of TIL were solely dependent on immunhisto-
chemisty, the introduction of the polymerase chain reac-
tion (PCR) in a semi-quantitative setting for analyses of
TCR variable regions set the stage for more comprehensive
analyses of TIL [15,16]. Numerous repertoire analyses of
various T-cell infiltrates have been conducted taking
advantage of semi-quantitative analyses of TCRBV or AV
usage [17,18]. The general findings provided by the use of
semi-quantitative analyses of the variable regions
expressed by TIL showed a skewed usage in comparison to
peripheral blood lymphocytes (PBL) [17,19-21]. How-
ever, data from such analyses are – at best – indicative for
an ongoing HLA restricted T-cell response, and the specif-
icity of any potential responses is merely suggestive.
Hence, although numerous studies included demonstra-
tion of clonality of TIL by cloning of TCR sequences fol-
lowed by sequencing, or even by direct sequencing
[17,19,22-25], the specificity and complexity of anti-
tumor T cells were left unrevealed.
Methods for analyses of clonally expanded T cells
High resolution techniques for the detection of clonally
expanded T cells are now available and established in
numerous laboratories. In general, these methods are
based on the RT-PCR amplification of T-cell receptor
CDR3 regions using primers for the variable region in
conjunction with a common primer for the constant part
of the receptor, followed by detection of increased num-
bers of TCR transcripts of a specific T cell. Several methods
are available for the swift detection and characterization
of clonally expanded T cells [26-29]. However, the two
most widespread methods are based on detection of
increased numbers of TCR transcripts having 1) identical
length (spectra typing or immunoscope) [18,30], or 2) dis-
tinct melting properties of the CDR3 region of the TCR
(clonotype mapping) [31-33]. Both methods are estab-
lished for human as well as murine TCRBV regions
[30,34]. Similarly, both methods are well suited for detec-
tion as well as quantitation of specific clonally expanded
T cells, and coupling to other techniques [35,36]. In addi-
tion, these methods provide the swift collection of PCR
products for direct sequencing that in turn may readily
form the basis for construction of clonotypic PCR primers
for real time PCR analyses [36,37]. Summing up the gen-
eral findings achieved by these high resolution techniques
when employed for analyses of TIL, it has become clear
that the T-cell infiltrate in tumor lesions comprise high
numbers of clonally expanded T cells [22,31], and unpub-
lished observations.
Since these early attempts to study the involvement of spe-
cific T-cell clonotypes in the immune response against
cancer cells, several important developments have pro-
moted the direct ex vivo assessments of tumor specific T
cells. First, the characterization of a high number of HLA
restricted peptides and the use of such peptides in vaccina-
tions against cancer imply that treatment induced specific
T cells are readily analyzed over the course of treatment
[38]. Second, the introduction of recombinant HLA mol-
ecules as tetra – or multimeric complexes coupled with
specific peptides, and the possibility to use these con-
structs for direct analyses and isolations of peptide specific
T cells enabled the clonotypic characterization of such
populations [36,39]. Finally, the means to employ the
ELISPOT methodology for functional analyses of T cells
made it possible to correlate functional aspects with the
results of analyses addressing the TCR repertoire usage
and clonality obtained by spectra typing or clonotype
mapping [36,40].
T-cell receptor utilization of tumor specific T cells in 
murine models
Although murine tumor models have been utilized in
cancer immunotherapy for several decades in pre-clinical
experiments, very limited data is available with regards to
TCR usage and clonality of tumor specific T cells; neither
spontaneously nor during therapy. Similarly, the number
of class I restricted tumor associated peptides character-
ized in murine tumors is devastating small compared to
human cancers [2,41-47]. Consequently, only a limited
number of murine studies have been conducted in which
TCRs of known specificity are scrutinized. The DBA/2
murine mastocytoma model P815 has been analyzed for
the TCR clonotypes involved in anti-tumor CTL responses
against specific antigens, taking advantage of the spectra
typing. Analyses of the infiltrate in this model revealed a
highly variable clonality among different mice. However,
a striking finding in this setting was the involvement ofJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/11
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two recurrent TCR rearrangements in the in vivo response
against P815 – emerging in almost all animals [48]. Direct
sequencing demonstrated that each of these "clonotypes"
were not absolutely monoclonal, but nevertheless in sev-
eral instances different CDR3 sequences coded for identi-
cal protein sequences, suggesting a strong selection for the
TCR protein in question. Moreover, these two recurrent
TCR rearrangements – called "public" – were present dur-
ing tumor progression as well as tumor rejection. One of
the TCR clonotypes recognized an epitope of the cancer/
testis antigen P1A [42]. Clearly, the recurrent selection of
identical TCRs in any given response suggests the involve-
ment of high affinity receptors [49], in turn indicating that
normal non-mutated self antigens may give rise to T-cell
responses that involve high affinity TCRs, at least when
studied in murine models. The stepwise progression of
human cancers implies that mechanisms of peripheral
tolerance may be at play – in transplanted murine tumors
such mechanisms are not likely to play an equally signifi-
cant role. Interestingly, the antigen recognized by the sec-
ond public TCR rearrangement was subsequently
characterized and shown to be a peptide which results
from a point mutation in the methionine sulfoxide
reductase (MsrA) [41].
Numerous studies of immunotherapy have been con-
ducted in the B16 melanoma model. Again, however,
only few studies have been conducted to analyze for T-cell
clonality against B16; treated as well as non-treated. TCR
clonotype mapping was used to analyze the clonality of
the T-cell infiltrate of B16 tumor treated with antibody tar-
geted IL-2. Compared to the P815 there was no evidence
for the involvement of public responses, but clonality was
only analyzed for the BV regions 5, 8, and 12 [50]. A more
recent study included the full panel of TCRBV regions in
clonotype analyses for studies of spontaneous T-cell
responses against B16 melanoma. In this study, more
than 600 clonotypic transcripts were compared, and none
of these clonotypes could recurrently be identified in
more than a single animal. Moreover, in this line of exper-
iments three tumors were induced in each animal, and
only a very limited number of clonotypes were detected in
more than one tumor in each animal. Hence, even when
analyzed in the same animal the response to each tumor
was largely unique [32].
In the same model, we recently analyzed T-cell responses
against B16 tumors when IL-2 is targeted to the tumor
microenvironment by means of specific antibody-IL-2
fusion proteins. Interestingly, the therapeutic effect of the
fusion protein was not restricted to tumors expressing the
targeted antigen, but extends to antigen negative variants
of the tumor in the same animal. Analysis of the T-cell
infiltrate by quantitative reverse transcription-PCR
revealed the presence of highly expressed TCR BV regions
in both tumor variants. TCR clonotype mapping revealed
that the high expressions of these regions were caused by
clonal expansions and, notably, that these specific clono-
typic TCR transcripts were identical in both tumors. Thus,
compared to the data from the analyses of non-treated
B16 lesions this suggests that T-cell clones activated
locally by targeted IL-2 therapy gain the capacity to re-cir-
culate and mediate eradication of distant tumor sites not
subjected to in situ cytokine therapy [34]. However, the
specificity and consequently direct evidence for the
involvement of the detected clonotypes in an ongoing
anti-tumor T cell was not revealed.
Using the same targeting approach against B16 melano-
mas, targeting of lymphotoxin α to the tumor site was
demonstrated to lead to the induction of an efficient
immune response, involving increased numbers of T-cell
clones among TIL over the course of treatment [51]. Data
from the analysis of the dynamics of the individual T-cell
clonotypes during treatment demonstrated the induction
of new clones during treatment but also the presence of
persistent of T-cell clones. Taking advantage of ELISPOT
analyses, the infiltrate in the tumors and draining lymph
nodes were demonstrated to comprise CTL specific for the
Kb/TRP2180–188 complex. Importantly, TRP2 specific CTL
responses were present in treated as well as un-treated
mice. Although specific reactivity was ten times higher in
treated animals this demonstrates that these responses
develop spontaneously [51].
A more comprehensive characterization of the T-cell
clonotypes in the response against tumor-associated anti-
gens in murine models awaits the molecular characteriza-
tion of the relevant peptides.
T-cell receptor utilization of tumor specific T cells in 
humans: spontaneous responses
As mentioned, several studies have been performed in
which the in vivo clonality of TIL – in particular in
melanoma – have been analyzed. Over the past few years
it has become well recognized that T-cell responses
develop spontaneously not only in melanoma but in
other cancers as well; that most if not all cancers elicit cel-
lular responses [3]. Nevertheless, it appears that some
antigens are spontaneously immunogenic, e.g., survivin,
her-2/neu, MUC-1, the melanocyte differentiation anti-
gens gp100 and Mart-1 [3], and ML-IAP [52], whereas
other antigens – like most members of the Mage family –
apparently do not elicit a measurable natural T-cell
response [3].
More than a decade ago, Sensi and colleges established
tumor specific CTL clones from HLA-A2 positive
melanoma patients [53]. By analyzing the lytic activity
against various melanoma target cells they demonstratedJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/11
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that TCRAV2/BV2 and TCRAV2/BV14 CTL clones were
restricted by the HLA-A2 molecule. Importantly, these
CTLs were shown to react not only against melanoma cells
but also against normal HLA-A2 positive melanocytes. As
suggested by the data given below this indicates that these
CTL specifically recognized the Mart-1/HLA-A2 peptide,
characterized independently by two research groups the
following year (1994) [54,55].
Clearly, antigens that elicit a spontaneous CTL response
offers the means to scrutinize these responses and reveal
further insight into the biology of natural immune
responses against cancer. Following the demonstration
that in vitro established Mart-1/HLA-A2 specific CTL fre-
quently express TCRBV14 [56], Salvi and colleges used
semi-quantitative PCR to analyze for expression of TCRBV
regions in tumor biopsies from HLA-A2 positive and neg-
ative melanoma patients [21]. Based on the assumption
that Mart-1 is immunodominant in the T-cell response
against melanoma and at the same time not knowing
whether other factors (e.g., other peptides also preferen-
tially recognized by TCRBV14 T cells) may have influ-
enced the predominance of TCRBV14 T cells, they
demonstrated a direct correlation between numbers of
TCRBV14 utilizing T cells and Mart-1 protein expression
in melanoma lesions in HLA-A0201 positive patients. In
spite of the fact that the clonality of the involved T cells
was not studied, it pointed to a scenario in which Mart-1
specific T cells – preferentially expressing TCRBV14 – took
part in the in situ anti-tumor response against melanoma
cells.
The long list of characterized human peptide antigens
expressed and presented on the surface of cancer cells,
offers the means to scrutinize the in situ presence of pep-
tide specific CTL. However, in some cases CTL clonotypes
reactive against autologous tumor cells – but nevertheless
of unknown peptide specificity – have been characterized.
In this respect, Mackensen et al. detected a TCRBV16 CTL
clone in situ in a case of regressive melanoma. The restric-
tion element of the the antigen was revealed to be HLA-
B14, but the protein and the peptide was not character-
ized [57]. Likewise, Pisarra el al., demonstrated tumor
specificity and cytotoxic capacity of an in situ expanded
TCRBV14 CTL clonotype in a HLA-A2 melanoma patient.
As given above, Mart-1 specific CTL predominantly
express BV14, however, neither the restriction element
nor the peptide was characterized [58].
More recent developments have offered the means to
combine specificiy of the T cell with analyses of clonality.
Valmori and colleges conducted a tetramer guided analy-
sis of the TCRBV region usage of Mart-1 specific T cells
[59], followed by a study from the same group focusing
on TCRBV chain clonality of these Mart-1 specific T cells
[60]. The general findings of these studies demonstrated
that the anti-Mart-1 T-cell response was highly diverse
although T cells expressing the BV14 region were predom-
inant; thus, confirming earlier reports from Salvi et al.
[21]. The involvement of numerous TCRs recognizing the
same HLA/peptide comples demonstrates the in vivo avail-
ability – and selection – of a high number of different
TCRs recognizing one HLA/peptide complex. Thus, these
data confirm the in vivo relevance of data from Romero et
al. demonstrating that in vitro established HLA-A1/Mage-
1 specific CTL may possess profound differences in their
fine specificity [61]. This also suggests lack of strong selec-
tion for specific TCRs in the response; conversely to the
results obtained by analyzing the response against the
MsrA and the P1A antigens in the murine P815 model, no
recurrent TCR sequences were identified among the
twelve patients analyzed [60]. Notably, the presence of
such selections, i.e. public TCRs, have only been described
in human T-cell responses directed against viral peptides
[62]. The background for the apparent discrepancy of viral
and anti-tumor responses remains unknown. One possi-
bility is that high affinity TCRs against self-antigens like
Mart-1 are removed during selection in the thymus, or
even by tumor-induced deletion [63], thereby eliminating
potentially dominant TCR clonotypes. Still, rather few
TCRs reactive against specific HLA/peptide complexes
have been extensively studied. Consequently, it is possible
that any conserved TCR usage could be more related to the
biochemical properties of the peptide than to the origin of
the peptide.
The occurrence of melanoma associated hypopigmenta-
tion is believed to be caused by T-cell responses specific
for melanocyte differentiation antigens, e.g., gp100 or
Mart-1. Indeed, by clonotype mapping we could demon-
strate the existence of clonally expanded T cells with iden-
tical BV regions accumulating in areas of destruction of
both normal, i.e. melanocytes, and neoplastic cells, i.e.
tumor cells [64]. As these clones supposedly are reactive
against antigens expressed on normal as well as neoplastic
cells, this observation demonstrates the quite unlimited
potential of the positively selected T-cell repertoire for
immunotherapy. To this end, vililigo patients have been
demonstrated to possess high frequencies of Mart-1 spe-
cific CTL [65]. In a recent study, Mantovani et al. scruti-
nized the Mart-1 CTL response in a vitiligo patient, and
demonstrated that a single TCRAV region constituted the
alpha chain in all Mart-1 specific CTL clones, and also that
these CTL persisted for more than 3 years in the patient
[66].
Interestingly, T cells participating in the immune response
against cancer are not restricted to the tumor site and the
sentinel lymph node. In this regard, we previously dem-
onstrated the recurrent indentification of a T-cell clone inJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/11
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melanoma lesions presenting in the patient with two
years interval. Moreover, the T-cell clone were present in
the sentinal lymph node of the first as well as the second
lesion [67]. Thus, the sentinel lymph node harbor T cells
that recognise the tumor, but the clones present in the
excised tissue were nevertheless maintained for almost 2
years in other compartments.
T-cell receptor utilization of tumor specific T cells in 
humans: treatment induced responses
Administration of cytokines has been used for the treat-
ment of malignant disease for many years. In this regard,
interleukin-2 is used for the treatment of malignant
melanoma as well as renal cell carcinoma, and systemic
administration of high dose IL-2 induce complete regres-
sion in a small but significant proportion of the patients
[68]. In spite of the widespread use of cytokines in clinical
oncology, not much is known with regards to the precise
immunological mechanisms associated with the in vivo
efficacy of IL-2 administration. A recent study suggested
that high dose IL-2 leads to activation of monocytes and
NK cells at the tumor site, in turn leading to the recruit-
ment of T cells [69]. However, very few studies have
focused on analyses of T cells over the course of cytokine
administration. We recently used the ELISPOT assay to
analyze for specific T-cell responses in melanoma patients
receiving low dose s.c. IL-2, in combination with local
electro-chemotherapy [36].
Surprisingly, specific reactivity in PBL as measured against
peptides derived from Mart-1, gp100, TRP-2, and survivin
decreased during IL-2 administration but re-occurred
between each IL-2 cycle. Intriguingly, analyses of the
clonotype composition of Mart-1 specific T cells by clono-
type mapping demonstrated that new clonotypes
occurred during treatment and that TRP-2 specific T cells
detected in the blood could subsequently be detected at
the tumor site. Together this indicates that IL-2 adds to the
capacity of T cells to home to the tumor site, and – impor-
tantly – questions the information gained alone by analy-
ses of blood samples. In a recent study, Willhauck et al.
studied the TCRBV repertoire of regressing melanoma
lesions after administration of IL-2 and INF-α [70]. How-
ever, as in the above mentioned study direct evidence that
establishes the link between the achieved data and the
treatment is lacking [20,71]. Nevertheless, in some
respects, analyses of immune reactivity during IL-2 repre-
sents an ideal model that could be used to gain novel
insight into clinically relevant anti-tumor immune
responses; the targets recognized, the phenotype and
clonotypic composition of tumor specific CTL, ect., that
may lead to improvements of more sophisticated immune
therapeutic strategies, e.g., therapeutic vaccinations
against cancer.
Sensi and colleges studied clonal expansions of T cells in
melanoma metastases after vaccination with hapten-mod-
ified autologous tumor cells [72]. Data from studies of
pre- and post vaccine tumor lesions demonstrated a more
intense inflammation, and also that expression levels of
specific TCRBV regions were markedly changed in post-
vaccine lesions. From one patient, several lesions were
analyzed over a two-year period and distinct clonotypes
were recurrently detected. Furthermore, TIL lines predom-
inantly expressing TCRBV14 were capable of lyzing autol-
ogous melanoma cells. Together this suggests a treatment
induced response, substantiated by data from a subse-
quent study of in situ T-cell clonality in melanoma
patients treated with DNP-modified autologous tumor
cells [73]. Examination of TCR repertoire and clonality in
post-vaccine metastases demonstrated a highly diverse
picture though specific clonotypes comprised up to more
than half of all T cells expressing the BV14 region. Strik-
ingly, specific clonotypes could recurrently be detected in
all (four) lesions in one of the patients.
The above mentioned data were recently further substan-
tiated by more comprehensive data on treatment induced
TCR clonality in response to vaccination with hapten-
modified autologous melanoma cells [74]. Thus, in 9 of
10 patients, analyses of post-vaccine biopsies showed
dominant expansions in several BV families, one of which
was BV14. Again, identical TCRs were detectable in biop-
sies obtained at different times or sites during treatment.
Clearly, these data suggest that the detected T-cell expan-
sions are indeed induced by the treatment. Although the
final prove for this notion is still lacking, it indicates that
vaccination based on autologous tumor cells induces a
highly diverse T-cell response, at least as judged by TCR
usage of responding T cells. Whether this indicates a cor-
respondingly diverse specificity of the response remain
unrevealed.
For studies of specific T-cell responses, e.g., clonality of
the response, peptide based vaccinations offer an ideal
setting. Such vaccinations have been ongoing for more
than a decade. The first peptide based vaccination trial
used subcutaneous administration of crude peptide [75],
while more recent peptide based vaccinations against can-
cer have taken advantage of various adjuvants in combi-
nation with peptide(s). However, data from studies of
TCR utilization are only available for very few peptide spe-
cificities. In this regard, Valmori et al. analyzed the
induced T-cell response in blood of melanoma patients
vaccinated with Mart-126–35  peptide administered i.m.
with SB-AS2 as adjuvant [76]. Characterization of the BV
clonotype composition of T cells stained with the Mart-1
tetramer over the course of treatment, demonstrated a pre-
dominance of T cells expressing BV1, 3, 5, 14, and 17.
These cells were expanded in vitro for three to four weeks,Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/11
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offering the opportunity to conduct functional analyses.
The downside of in vitro culture is obvious; not all CTLs –
for some populations probably only a minority – will be
supported by in vitro growth conditions [77,78]. However,
this shortcoming was taken into account in the study of
Valmori et al., by comparing the BV repertoire and CDR3
spectra before and after in vitro culture. Thus, although the
BV1 T cells were lost in culture, most in vivo clonotypes
were preserved. Subsequent sequencing offered the means
to investigate whether Mart-1 T cells detected in periph-
eral blood could recurrently be detected at the tumor site,
and indeed this was the case. Also, the tracking of specific
clonotypes provided the means to gain insight into the
dynamics of the induced CTL response, demonstrating a
highly asynchronous expansion of responding T cells.
Interestingly, the functional avidity increased during vac-
cination, however, the mechanism(s) were left unre-
vealed. Clearly, it would be of interest to evaluate the
clonotypes comprised in the spontaneous Mart-1
response and compare these clonotypes to those induced
by treatment to reveal whether the increase in functional
avidity was merely due to induction of T cells not taking
part in the spontaneous response. To this end, Terheyden
et al., conducted a longitudinal study of Mart-1 specific T
cells over the course of melanoma progression in a patient
vaccinated with dendritic cells pulsed with peptides [79].
The tracking of Mart-1 clonotypes from onset of treatment
demonstrated the persistence of TCRBV2 and BV14 clono-
types [80]. Moreover, the percentage of TCRBV14 cells
capable of producing INF-γ before treatment was 9%, but
increased to 52% during treatment, and declined to 11%
upon severe disease progression. Clearly, neither the study
of Valmori et al., nor the study by Terheyden and colleges
studied the complete Mart-1 specific CTL population.
Still, it points to a scenario in which vaccination may not
only induce the expansion of CTL not involved in the
spontaneous response, but possibly also alter the func-
tionality of pre-existing specific CTL.
Vaccinations using peptides derived from cancer/testis
antigens, in particular peptides derived from Mage pro-
teins, have been ongoing for more than a decade, and the
T-cell response intensively studied [81]. In two recent
reports the clonality of vaccine induced Mage-specific T
cells were analyzed [82,83]. Godelaine and colleges scru-
tinized the T-cell repertoire in four melanoma patients
vaccinated with DCs loaded with Mage-3/HLA-A1 peptide
[83]. Taking advantage of tetrameric complexes, specific T
cells were cloned, expanded in vitro, and the TCRB
sequence determined. In three of the four patients exam-
ined, a specific response was induced and TCR clonality
analyzed. In each patient Mage-3/HLA-A1 specific T-cell
populations were characterized by expression of several
distinct TCR chains, but also that a single TCR comprised
from above 30 to app. 50 % to of the responding cells.
Thus, although several discrete T cells were activated dur-
ing vaccination, some clones were clearly more abundant.
Coulie et al. analyzed a single patient vaccinated with the
same HLA-A1 restricted peptide, however, administered
s.c. and intradermally as crude peptide [82]. There was a
vigorous increase in the frequency of specific CTL, how-
ever, this T-cell response was monoclonal, as judged after
in vitro stimulation. The patient experienced regression of
several metastatic sites, but also simultaneous progression
of others. Tracking by clonotypic PCR demonstrated that
this specific clone was present even at progressive tumor
sites and studies of the expression of antigen and HLA by
the tumor cells, demonstrated that (some of...) the prereq-
uisites for T-cell recognition were fulfilled. The different
results concerning clonality of the two studies mentioned
above raises the question whether this is a reflection of
DC based vaccination versus the use of crude peptide.
Considering the very limited number of patients analyzed
it remains to be elucidated whether these marked differ-
ences in clonality are reflections of the two vaccination
protocols – or merely differences among the patients.
However, it could be speculated that the DC based
approach are more prone to provide sufficient help for the
expansion of CTLs of relative low affinity – and that the
crude peptide approach only activates a narrow repertoire
of T cells carrying high affinity receptors. Our own previ-
ous results for DC based vaccination sustain this hypoth-
esis regarding DCs. In fact, in vitro matured and antigen-
pulsed DCs inoculated in the skin are able to induce a
peptide specific oligoclonal T-cell response in the dermal
compartment [84]. Nevertheless, these studies emphasize
the strength of combining the use of recombinant HLA
molecules with clonotype analyses of responding T cells.
Berger and colleges studied the TCR repertoire in a
melanoma patient vaccinated with HLA-A2, and HLA-A24
restricted peptides of several tumor antigens, i.e., peptides
from Mart-1, tyrosinase, and Mage-3 [85]. Mart-1 specific
T cells – as determined by staining with multimeric pep-
tide/HLA complexes – were present in the lesions prior to
vaccination, but the numbers increased substantially after
vaccination. Moreover, Mage-3/HLA-A2 specific T cells
were not detectable prior to vaccination, but became
apparent after vaccination. Interestingly, analyses of the
clonal composition of the T-cell infiltrate in a cutaneous
and a visceral lesion demonstrated the presence of identi-
cal TCR clonotypes in these two lesions. Clearly, this indi-
cates that distinct homing marker profiles may develop
during the response – most likely independent of the
priming event. It should be noted that the T-cell clone
present in the metastases could be detected in the circula-
tion as well; however, no quantification of these cells were
performed, thus, no correlation between circulating andJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/11
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in situ T-cell responses can be drawn from this observa-
tion.
Another immunotherapeutic approach in cancer is the
adoptive transfer of (potentially) tumor specific T cells.
Early attempts pursueing this approach took advantage of
in vitro expansion of autologous TIL or PBL and the subse-
quent transfer of cells to the patient. However, despite
some success in preclinial models [86], the response rates
observed in the human setting were not encouraging [87].
However, the adoptive transfer of in vitro expanded TIL in
combination with high-dose IL-2, administered subse-
quent to non-myeloablative chemotherapy, was recently
demonstrated to induce objective clinical responses in 6
out of 13 melanoma patients [88]. Importantly, all cul-
tures were analyzed for the capacity to recognize autolo-
gous or HLA-matched tumor cell targets prior to
administration. Data from TCR repertoire analyses of the
adminstered TIL cultures demonstrated at skewed BV
region usage in five of six patients. Moreover, in two of the
patients specific T-cell clonotypes were monitored and
demonstrated to expand in vivo. Thus, in these two
patients Mart-1/HLA-A2 T-cell clones comprised more
than 60% of the CD8 population for more than 4 months.
Clearly, such high frequencies are way above CTL frequen-
cies obtained by any other means of immunotherapy
against cancer, and indeed several of the patients experi-
enced autoimmunity (vitiligo/uveitis). Strikingly, a simi-
lar treatment strategy was previously persued by the same
group, however, by administration of in vitro expanded T-
cell clones [89]; none of the 15 patients included
responded clinically. Although larger trials are required to
make firm conclusions, it could point to a significant role
of CD4 cells in the administered cultures – in turn under-
lining the importance of establishing methods for moni-
toring and tracking of tumor specific CD4 T-cell
clonotypes [90].
Analyses of TCRBV versus TCRAV: Does it matter?
Most studies addressing the TCR repertoire usage have
been conducted with an emphasis on BV regions. Consid-
ering PCR based methods this is actually not optimal:
there is a high degree of homology between the different
BV regions, and several BV families comprise numerous
members, implying that specific PCR amplification of all
family members without cross reactivity to other BV fam-
ilies, is not entirely trivial. Conversely, TCRAV families
comprise relatively few members and homology between
the families is low compared to TCRB families [13]. Early
data on virus specific T cells and TCRBV usage, demon-
strated a preferential usage of specific BV regions; these
data may have influenced the field with regards to
whether AV or BV chains should be studied [62,91]. Irre-
spective of the reason, most researchers have conducted
clonality and repertoire analyses of the TCRB chain.
Recently, a dominant role of the TCRAV chain in the rec-
ognition of HLA/peptide complexes was demonstrated
[92-94]. Analyses of V region usage and CDR3 region con-
servation in T cells specific for viral as well as tumor asso-
ciated peptide/HLA-A2 revealed a recurrent use of AV
regions, a more heterogeneous usage of BV regions, and
highly diverse junctional sequences [92]. Likewise, Traut-
man and colleges found a frequent usage of TCRBV14 by
Mart-1 specific T cells, but a much more prominent usage
of TCRAV2.1. Strikingly, Dietrich et al. similarly analyzed
Mart-127–35/HLA-A2 specific T cells and found a strong
selection for TCRAV2.1 also in cord blood, out ruling that
the narrow repertoire was developed by affinity focusing
[93].
These data suggests a prominent role for the TCRA chain
for determining the specificity of the receptor. In some
respects this seems self explanatory due to the fact that the
TCRB chain re-arrange prior to the TCRA chain. This
implies that any TCRB may eventually be associated with
multiple TCRA chains. Consequently, if the TCRB were
the important determinant of specificity, T cells carrying
identical TCRB and different TCRA would have a high risk
for identical specificity. In any case, final prove for any
general TCRA – or B bias and their roles as determinants
of specificity awaits further TCR/peptide/MHC structures
to be revealed [95]. Interestingly, it was recently demon-
strated that a "public" TCR is highly predominant in CTL
responses against the dominant EBV peptide restricted by
HLA-B8, and germline encoded parts of the TCR was dem-
onstrated to be involved in recognition [96,97]. This
touches on whether such TCRs – heavily influenced by
germline sequences – are evolutionarily selected, and
therefore such responses could possibly be quite different
than responses against e.g., self antigens associated with
cancer.
Concluding remarks
Data from molecular analyses of T-cell clonotypes in var-
ious clinical infiltrates have over the past years contrib-
uted to our understanding of cellular immune responses.
However, whereas previous data were merely descriptive,
present days technical and methodological advances offer
the possibility to by combine phenotype and functional
data with analyses of TCR repertoire and clonality.
"Molecular fingerprinting" of T cells with known specifi-
city offers the means to reveal a more sophisticated and
instructive picture of ongoing T-cell responses by covering
spatial and temporal dynamics. Certainly, such data will
significantly increase our understanding of the cells and
molecules that govern anti-cancer T-cell responses thereby
leading the way to improve immune therapeutic strategies
to combat cancer.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/11
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